Market
Potential and Pitfalls
The global autoimmune disease
diagnostics market is likely to experience an upsurge owing to the increased
prevalence of autoimmune disease, surging awareness regarding autoimmune
diseases, and rising expenditure on healthcare. The increasing spending on
R&D activities coupled with the aggressive strategies adopted by the top
market players like new product launches along with mergers and acquisitions
are anticipated to contribute to the market growth across the globe. For
instance, Abbott acquired Alere Inc. in October 2017 for USD 5300 million. The
deal will enable Abbott to gain control over USD 7000 million diagnostics sales
of Alere Inc. and also strengthen their position in the global market.
The
increasing occurrences of several diseases like rheumatoid arthritis and
Hashimoto’s thyroiditis are likely to influence the market across the globe.
Several initiatives taken by the government regarding autoimmune disease
diagnosis are further contributing to its growth. As per the American
Autoimmune Related Diseases Association, approximately 50 million people from
America are suffering from autoimmune related disorders. Such factors are
likely to create immense opportunities to the growth of the market.
On the contrary, the surging false
positive results along with the price war among the companies are the top
barriers likely to vitiate the market growth to some extent during the
appraisal period. Moreover, the dearth of education and experience of the lab
personnel in diagnosing certain autoimmune diseases are further estimated to
slow down the market growth.
Request
For Free Sample Report: https://www.marketresearchfuture.com/sample_request/6715
Market
Synopsis
Market Research Future (MRFR) asserts
that the global autoimmune disease diagnostics market is likely to register a
CAGR of 7.6% during the forecast period (2018-2023) owing to an increased
prevalence of autoimmune diseases worldwide. Autoimmune disease is considered
as a disorder where the body’s own immune system starts to attack the healthy
cells in place of the foreign particles and disease-causing agents. Auto
antibody test, antinuclear antibody test, complete blood count, C-reactive
protein, and erythrocyte sedimentation rate are some of the tests performed for
diagnosis of the autoimmune disease.
Global
Autoimmune Disease Diagnostics Market: Segmental Analysis
The global autoimmune disease
diagnostics market has been segmented on the basis of test type, disease type,
and end-user.
By mode of disease type, the global
autoimmune disease diagnostics market has been segmented into systemic
autoimmune disease, and localized autoimmune disease. Among these, the
localized autoimmune disease segment is likely to gain prominence owing to the
presence of large procedure volume and higher patient awareness level.
By mode of test type, the global
autoimmune disease diagnostics market has been segmented into enzyme-linked
immunosorbent assay (ELISA), western blotting, dot blot, double immune
diffusion, line blot, counter immune-electrophoresis, multiplex immunoassay,
immunofluorescence assays (IFA), agglutination, and others.
By mode of end-users, the global
autoimmune disease diagnostics market has been segmented into diagnostics
centers, hospitals, research laboratories, and others.
For More
Details Browse Complete Report @ https://www.marketresearchfuture.com/reports/autoimmune-disease-diagnostics-market-6715
Regional
Insights
Geographically, the autoimmune disease
diagnostics market span across regions namely, Europe, America, Asia-Pacific,
and the Middle East & Africa.
Considering the global scenario, the
American region is predicted to command the maximum share in the global market.
The region is likely to retain its pole position owing to the surging
prevalence of autoimmune diseases like rheumatoid arthritis. Moreover, the
rising financial support by the private organizations and governments coupled
with the adoption of high advanced technology in this region is anticipated to
contribute to the growth of the market. As per a report published by the
Arthritis Foundation in 2017, around 91 million Americans were suffering from
arthritis, 300000 of them were children.
The European region is predicted to
occupy the second spot in the global market owing to the increased automation
in the laboratories, rising healthcare industry, and strategies implemented by
the top market players like mergers & acquisitions and product launches.
The Asia Pacific region is likely to
expand at the fastest growth rate during the assessment period. The growth can
be ascribed to the inflating population, rising private-public partnerships for
the improvement of the healthcare sector, and surging prevalence of autoimmune
disorders in this region.
Industry
Updates
March 27,
2019: Eli Lilly is planning to partner with ImmuNext in order to study and
develop a preclinical novel potential target for the treatment of autoimmune
disease through an up-to-$605 million-plus collaboration.
Competitive
Dashboard
The prominent
players operating in the global autoimmune disease diagnostics market comprises
bioMérieux SA, Siemens Healthcare Private Limited, Beckman Coulter Inc.,
Bio-rad Laboratories, EUROIMMUN AG, AstraZeneca, Inova Diagnostics Inc., F.
Hoffmann-la Roche, Thermo Fisher Scientific, Myriad Genetics Inc., Hemagen
Diagnostics Inc., and Trinity Biotech Plc.
No comments:
Post a Comment